TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté sam. 29 août · 17:00 UTC+2Hot Line 4Tous les essais Hot Line →

TARGET-CTCA

2026

Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography (TARGET-CTCA)

In 3,170 patients with suspected ACS, infarction ruled out and an intermediate troponin, outpatient CT coronary angiography did not reduce myocardial infarction or cardiac death compared with standard care.

Résultat

Efficacité: Composite of myocardial infarction or cardiac death (time to first event)adjusted HR 0,95 (IC à 95 % 0,73-1,23) · P = 0,71

En dessous de 1 en faveur de outpatient CT coronary angiography, au-dessus de 1 en faveur de standard care.

Taux d’événements
Différence absolue
0,2 points

La différence absolue est dérivée des taux d’événements.

Également rapporté: Myocardial infarction or cardiac death after a median 3.0 years . CT coronary angiography was performed within 90 days in 92.1% of the CT group and 2.2% of the standard-care group; 0.4% had a CT-related adverse event.

Publication originale
Sous-thème
CT coronary angiography
Schéma
Multicentre (14 UK hospitals), prospective, randomised, open-label, blinded-endpoint (PROBE), parallel-group, event-driven superiority trial; 1:1 allocation to outpatient CTCA plus standard care or standard care alone; minimum 24 months and median 36 months follow-up; powered on 97 primary-outcome events in the standard-care arm
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Lee KK, Wereski R, Lowe DJ, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2608903

Discussion et critique

Ruling out infarction leaves a patient with an intermediate troponin and no answer, and the intuition is to look at the arteries. Over three years that look changed nothing: 7.1% against 7.3%, with a separation of 90 percentage points in who actually got scanned, so this is a real test of the strategy rather than a diluted one. The interval runs to 1.23, which leaves room for a small benefit but not for the one that would justify scanning everyone; what the trial does not address is whether a targeted subgroup, or a different response to what the scan finds, would fare differently.

Discuté dans des podcasts